Skip to content

Fluoxetine vs. Brief Psychotherapy for Major Depression

Fluoxetine vs. Brief Psychotherapy in the Treatment of Major Depression - a Randomized Comparative Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00714779
Enrollment
85
Registered
2008-07-14
Start date
2000-01-31
Completion date
2004-12-31
Last updated
2008-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

Major depressive Disorder, fluoxetine, short-term psychodynamic psychotherapy, PET

Brief summary

In this study we compare two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before and after the treatment. The main hypothesis is that brief psychotherapy is as effective as fluoxetine.

Detailed description

This study is a randomized comparison of two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. The patients are recruited from occupational health services and suffer from mild to moderate major depressive disorder. The treatments last for 16 weeks. The main outcome measures include HAM-D, BDI, SOFAS, Rand-36. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before and after the treatment using Positron Emission Tomography (PET) . The main hypothesis is that brief psychotherapy is as effective as fluoxetine, but differences between the treatments are seen in PET scanning.

Interventions

DRUGFluoxetine

20-40 mg / day orally

BEHAVIORALShort-term psychodynamic psychotherapy

1 session / week for 16 weeks

Sponsors

KELA
CollaboratorUNKNOWN
Finnish State Grant
CollaboratorUNKNOWN
University of Turku
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* MDD (mild to moderate) * HDRS 15 or more, age 20-60 years * No treatment for preceding 4 months * No DSM-IV axis I or II comorbidity * No severe somatic illness * No contraindications for fluoxetine treatment

Design outcomes

Primary

MeasureTime frame
HAM-D0, 16 weeks, one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026